Moderna Inc. Logo
US60770K1079
A2N9D9
MRNA

Moderna Inc.

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 99,63 € (-19,82%). La mediana è 105,49 € (-15,11%).

Acquista
  8
Mantieni
  16
Vendi
  5

  • Bamco bought Moderna before shares nearly tripled

    Bamco, the advisory arm of Baron Capital Group, opened a new roughly 2 million‑share position in Moderna during Q2 2026. The timing proved favorable as Moderna stock almost tripled in August following a positive Phase 3 trial report. » Altro su finance.yahoo.com


  • Moderna closes $3 billion convertible notes and shares jump

    Moderna privately placed interest-free convertible notes totaling $3 billion (including an exercised option of $400 million) maturing in March 2032 with an initial conversion price of about $211 per share. Net proceeds of roughly $2.96 billion will, according to the company, go to the oncology division and debt reduction; about $329 million were used for cap hedges against dilution. If fully converted, up to approximately 14.2 million new shares could be issued; investors will watch the conversion price as a reference for potential future dilution. » Altro su finanzen.net


  • Moderna closes $3 billion convertible bond and expands oncology unit

    Moderna placed a zero‑coupon convertible bond totaling $3 billion (including a $400 million option) maturing in March 2032; the initial conversion price is about $211 per share. Net proceeds will be used to strengthen the oncology unit and to pay down debt; roughly $329 million went into cap hedges against dilution (cap price about $393). The stock jumped nearly 10% on the announcement before an after‑hours pullback, after positive Phase‑III data for the cancer vaccine Intismeran had already driven strong gains. If fully converted, up to about 14.2 million new shares could be issued, representing potential dilution for shareholders. » Altro su finanzen.net

Nel 2022, Moderna Inc. ha già distribuito 0,17 € di dividendi. L'ultimo pagamento è avvenuto a maggio 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Moderna Inc. ha registrato ricavi pari a 127,05 Mln € e un utile netto di -685,2 Mln €
(EUR) giugno 2026
YoY
Ricavi 127,05 Mln 5,46%
Utile lordo 45,56 Mln 133,49%
Utile netto -685,2 Mln 2,11%
EBITDA -616,85 Mln 4,33%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
49,73 Mld €
Numero di azioni
396,79 Mln
Massimo/minimo a 52 settimane
152,12 € - 19,19 €
Dividendi No
Beta
0,90
Rapporto P/E
-18,24
Rapporto PEG
2,16
Rapporto P/B
8,53
Rapporto P/S
25,92

Profilo aziendale

Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome
Moderna Inc.
CEO
Stéphane Bancel
Sede centrale Cambridge, ma
Stati Uniti
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
07/12/2018
Dipendenti 4700

Simboli di borsa

Borsa Simbolo
NASDAQ
MRNA
XETRA
0QF.F
Frankfurt
0QF.F
Düsseldorf
0QF.DU
Hamburg
0QF.HM
Milan
1MRNA.MI
London
0A45.L
SIX
0QF.SW
München
0QF.MU
Wien
MRNA.VI
🍪

Parqet  usa i cookie. Scopri di più